Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | MPL proto-oncogene, thrombopoietin receptor | Starlite/ChEMBL | References |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Mycobacterium tuberculosis | NADH-dependent enoyl-[acyl-carrier-protein] reductase InhA (NADH-dependent enoyl-ACP reductase) | 0.0192 | 0.5 | 0.5 |
Trichomonas vaginalis | hypothetical protein | 0.0192 | 0.5 | 0.5 |
Plasmodium vivax | enoyl-acyl carrier protein reductase | 0.0192 | 0.5 | 0.5 |
Mycobacterium ulcerans | enoyl-(acyl carrier protein) reductase | 0.0192 | 0.5 | 0.5 |
Mycobacterium leprae | NADH-DEPENDENT ENOYL-[ACYL-CARRIER-PROTEIN] REDUCTASE INHA (NADH-DEPENDENT ENOYL-ACP REDUCTASE) | 0.0192 | 0.5 | 0.5 |
Wolbachia endosymbiont of Brugia malayi | enoyl-ACP reductase | 0.0192 | 0.5 | 0.5 |
Plasmodium falciparum | enoyl-acyl carrier reductase | 0.0192 | 0.5 | 0.5 |
Toxoplasma gondii | enoyl-acyl carrier reductase ENR | 0.0192 | 0.5 | 0.5 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.